Publications by authors named "F Repetto"

Western equine encephalitis is a zoonotic viral disease transmitted by the bite of an infected mosquito. Humans are terminal hosts and since they develop a very low and short lasting viremia, they are incapable of transmitting the disease. Most cases are asymptomatic, but it can present with high fever, myalgia and encephalitis or meningitis.

View Article and Find Full Text PDF

Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current treatment options for HS are limited, as only adalimumab and secukinumab are approved for severe cases. Given the overlapping pathogenetic features between HS and psoriasis, anti-IL-17 and anti-IL-23 drugs could represent valuable treatments for the management of HS.

View Article and Find Full Text PDF
Article Synopsis
  • Spindle cell-rich testicular sex cord-stromal tumors (TSCSTs) include types like myoid gonadal stromal tumor (MGST), adult granulosa cell tumor (AGCT), and unclassified TSCST, showing histopathologic similarities and lacking clear oncogenic drivers.
  • DNA sequencing indicates common chromosomal gains in these tumors, but further validation of these findings has not yet taken place, and the amount of chromosomal alterations varies among individual tumors.
  • This study used fluorescence in-situ hybridization (FISH) to assess chromosomal changes in 10 tumors, revealing consistent increases in specific chromosomes across various cases, while also uncovering partial disagreements between FISH analysis and previous genomic sequencing results,
View Article and Find Full Text PDF

Real-world data on the long-term effectiveness of the anti-IL17 agent secukinumab in treating moderate-to-severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate-severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12-week intervals.

View Article and Find Full Text PDF